Conivaptan: YM 087

Drugs in R and D

Volumn 5, Issue 2, 2004, Pages 94-97

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN RECEPTOR; ATORVASTATIN; BENZAZEPINE DERIVATIVE; CONIVAPTAN; FUROSEMIDE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DIURETIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENCY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; LICENSING; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SIDE EFFECT; URINE VOLUME;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HUMANS; METABOLIC DISEASES; RANDOMIZED CONTROLLED TRIALS; RATS; RECEPTORS, VASOPRESSIN;

EID: 2342608998     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405020-00005     Document Type: Article

References (13)

1. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. American Heart Journal 145: 179-186, Jan 2003
2. Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087 a combined V1/V2 vasopressin receptor antagonist in normal subjects. European Journal of Clinical Pharmacology 55: 633-637, Nov 1999
3. Abraham W, Suresh DP, Wagoner LE, et al. Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally. European Heart Journal 21 (Abstr. Suppl.): 345, Aug-Sep 2000
4. Tonkon M, Aronoff G, Weisfogel G, et al. Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure. European Heart Journal 22 (Abstr. Suppl.): 541 [plus poster], Sep 2001
5. Tanaka A, Taniguchi N, Matsuhisa A. 1,4,5,6-Tetrahydro imidazo[4,5-d][1]benzazepine derivatives: highly potent, orally active antagonists of arginine vasopressin receptors. Part 2. 211th American Chemical Society National Meeting 211: abstr. 139, 24 Mar 1996
6. Wada K-i, Tomura Y, Tahara A, et al. Effects of YM087, a novel nonpeptide arginine vasopressin V1A/V2 receptor antagonist, in normal rats and in rats with congestive heart failure after myocardial infarction. Japanese Journal of Pharmacology 71 (Suppl. 1): 227, 1996
7. Tahara A, Tomura Y, Wada K-i, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovascular Research 38: 198-205, Apr 1998
8. Tomura Y, Tahara A, Tsukada J. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clinical & Experimental Pharmacology and Physiology 26: 399-403, May-Jun 1999
9. Yatsu T, Tomura Y, Tahara A. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V-1A and V-2 receptor antagonist, in dogs with pacing-induced congestive heart failure. European Journal of Pharmacology 376: 239-246, 9 Jul 1999
10. Wada K, Tahara A, Arai Y, et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. European Journal of Pharmacology 450: 169-177, 23 Aug 2002
11. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423, 13 Nov 2001
12. Abraham W, Koren M, Bichet DG, et al. Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist. European Heart Journal 21 (Abstr. Suppl.): 345, Aug-Sep 2000
13. Painchaud C, Bichet D, Udelson JE, et al. Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure. European Heart Journal 22 (Abstr. Suppl.): 394 [plus poster], Sep 2001